Chiesi in Australia
Chiesi Australia is the Australia-New Zealand division of the Chiesi Group, a global pharmaceutical company based in Parma, Italy. The Chiesi Group acquired Emerge Health in November 2019 to form the Australian affiliate.
In Australia, Chiesi has a workforce of over 90 people employed directly or indirectly with chosen partners, who are based out of our head office in Melbourne and across Australia as part of our experienced field-based sales teams.
Chiesi Farmaceutici S.p.A. is an international, research-based, pharmaceutical company, based in Parma, Italy. With over 80 years’ experience, Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases. With a turnover of €1,993M, Chiesi are among the top 50 pharmaceutical companies in the world1.
The Company was founded in 1935, as a family firm. Today Chiesi spans the globe, employing more than 6,000 people in 27 affiliates worldwide and provides access to its products in more than 80 countries1.
Chiesi embrace innovation, which is a constant driver to its continued success. Products wholly, or partially, developed by Chiesi account for 81% of the sales1, and investment in Research and Development currently stands at a record €378,3M. Chiesi ‘firsts’ include the first stem cell product approved in Europe and new options for serious genetic diseases.
Chiesi Ltd. was established in 1999 with the acquisition of Trinity Pharmaceuticals (by Chiesi S.p.A), whose ethos, values and specialist expertise perfectly complemented those of the wider Chiesi group.
1. Chiesi.com (Accessed June 2020)